Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 23, 2023
Information
Tags: 
Surgery, Hospitals, Clinical Trials, Cardiology, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Gauge, JAGUAR, Metaphilosophy, Aortic aneurysm, AAA, Patient, Randomized controlled trial, Vascular disease, EVAR, Medical imaging
Geotags: 
CALIFORNIA, UNITED STATES, NORTH AMERICA
⚠ partially generated by AI ↴
Summary
Key Points: 
  • This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).
  • The JAGUAR (ObJective Analysis to GaUge EVAR Outcomes Through Randomization) Study is a prospective, randomized, multi-center study, designed to enroll 450 patients at up to 60 sites.
  • "This milestone for Endologix underlines our dedication to clinical research and patient care," stated Matt Thompson, President, and CEO of Endologix.
  • “The JAGUAR trial, our second randomized study aimed at assessing comparative endograft performance, follows in the footsteps of our successful LEOPARD study.


Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the completion of the 150th case in the JAGUAR Study. This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).

The JAGUAR (ObJective Analysis to GaUge EVAR Outcomes Through Randomization) Study is a prospective, randomized, multi-center study, designed to enroll 450 patients at up to 60 sites. Three hundred patients will be randomly assigned to the ALTO cohort, with 150 allocated to the comparator group. The study will follow-up patients through five years, with outcomes independently adjudicated.

"This milestone for Endologix underlines our dedication to clinical research and patient care," stated Matt Thompson, President, and CEO of Endologix. “The JAGUAR trial, our second randomized study aimed at assessing comparative endograft performance, follows in the footsteps of our successful LEOPARD study. We strongly believe in ALTO's role in managing AAA, given its low-profile, wide applicability within EVAR and in the durability of the adaptive sealing technology. These evaluations are instrumental in shaping optimal treatment strategies and enhancing patient outcomes."

About the ALTO Abdominal Stent Graft System

Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients. ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive Adaptive Sealing Technology that molds in-situ to the patient’s specific aortic neck anatomy.

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. These products are designed to treat a wide spectrum of vascular disease from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix’s current commercial EVAR products include the AFX®2 Endovascular AAA System and the ALTO® Abdominal Stent Graft System. On October 1, 2020, Endologix became a private company, wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. In April 2021, Endologix completed the acquisition of PQ Bypass, Inc., a privately held medical technology company, adding the DETOUR System and TORUS Stent Graft to the Company’s product pipeline. The DETOUR System and the TORUS Stent Graft have not been approved for sale by any regulatory body. The DETOUR System is an investigational device, limited by United States law to investigational use.

The company has offices and manufacturing sites in Irvine and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

Copyright: 
Copyright Business Wire 2023